Comparative Pharmacology
Head-to-head clinical analysis: DEXAMPEX versus QUILLIVANT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMPEX versus QUILLIVANT XR.
DEXAMPEX vs QUILLIVANT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextroamphetamine is a central nervous system stimulant that increases extracellular dopamine and norepinephrine levels by blocking their reuptake and promoting release from presynaptic terminals.
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
5-10 mg orally once daily in the morning, maximum 20 mg/day.
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
None Documented
None Documented
Terminal elimination half-life 10–13 hours in adults (7–8 hours in children). Longer in alkaline urine (up to 20 hours) due to reduced renal tubular reabsorption.
Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours.
Renal: ~90% as unchanged drug and metabolites (primarily deaminated metabolites); fecal/biliary <2%.
Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%.
Category C
Category C
CNS Stimulant
CNS Stimulant